Procter & Gamble Health Ltd

  • BSE Code : 500126
  • NSE Symbol : PGHL
  • ISIN : INE199A01012
  • Industry :PHARMACEUTICALS - MULTINATIONAL

up-arrow 5,433.00 21.50(0.40%)

Open Price ()

5,405.00

Prev. Close ()

5,411.50

Volume (No’s)

6,247

Market Cap ()

8,982.76

Low Price ()

5,363.50

High Price ()

5,459.00

 

Board Meetings

Start Date End Date Purpose
26-Jun-2026 06-Aug-2026 Procter & Gamble Health Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 inter alia to consider and approve Dear Sir In terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday August 6 2026 inter alia to consider and approve unaudited Financial Results for the quarter ended June 30 2026. Kindly take the same on record. Outcome of Board Meeting. (As Per BSE Announcement Dated on: 06/08/2026)
27-Mar-2026 26-May-2026 Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 ,inter alia, to consider and approve Intimation of Board Meeting scheduled to be held on May 26, 2026 We are enclosing herewith the following: a. Audited Financial Results for the Financial Year ended March 31, 2026, as per format prescribed under Regulation 33 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015; b. Auditor's Report, in respect of the aforementioned Financial Results, as furnished by the Statutory Auditors of the Company; c. A declaration with respect to Audit Report with unmodified opinion to the aforementioned Audited Financial Results We are pleased to further inform you that the Board of Directors of the Company at its meeting held today, inter alia, have recommended a dividend of Rs. 45 per Equity Share (Nominal Value of Rs. 10/- each), for the Financial Year ended March 31, 2026. The divided shall be paid on or before September 25, 2026, on approval of the Members at the ensuing Annual General Meeting. In terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we would like to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, May 26, 2026, inter alia, to consider and approve Audited Financial Statements for the Financial Year ended March 31, 2026 and to consider recommendation of final dividend (if any). (As Per BSE Announcement Dated on 26.05.2026)
26-Dec-2025 06-Feb-2026 Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 ,inter alia, to consider and approve The meeting of the Board of Directors of the Company is scheduled on 06/02/2026, inter alia, to consider and approve unaudited financial results for the quarter ended December 31, 2025. Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 ,inter alia, to consider and approve Update on board meeting to be held on February 6, 2026. We are enclosing herewith the following: a. Unaudited Financial Results; b. Limited Review Report in respect of the Unaudited Financial Results furnished by Statutory Auditors of the Company. Further, we are pleased to inform you that the Board of Directors of the Company at its meeting held today, inter alia, have declared an Interim Dividend for the Financial Year 2025-26 of Rs. 160 per Equity Share (including a one-time special dividend of Rs. 50 per Equity Share). The dividend shall be paid on or before March 4, 2026. (As Per BSE Announcement Dated on: 06/02/2026)
29-Sep-2025 05-Nov-2025 Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2025 inter alia to consider and approve Intimation of Board Meeting scheduled to be held on November 5 2025 Purpose of the meeting has been revised Further to our letter dated September 29, 2025, regarding the Board meeting scheduled on November 5, 2025, this is to inform you regarding revision in the items proposed to be considered by the Board at the said meeting. The agenda for the meeting of the Board of Directors will now include only following item from the items listed under Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015: 1. Approval of the Unaudited Financial Results for the quarter ended September 30, 2025. (As per BSE Announcement dated on: 20.10.2025) Outcome of Board Meeting for the quarter ended September 30, 2025 Outcome of Board Meeting held for the quarter ended September 30, 2025 (As Per BSE Announcement Dated on:05.11.2025)
16-Sep-2025 16-Sep-2025 Appointment of Mr. Shashank Srowthy as Executive Director and Chief Financial Officer of the Company, effective October 1, 2025 in place of Mr. Lokesh Chandak.

Copyright © 2026 Arihant Capital Markets Ltd. All rights Reserved.

Designed, Developed and Content powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)

x
  • QR-CodeNew